Feedback / Questions
BGE-102 - BioAge Labs
https://www.globenewswire.com/news-release/2025/08/15/3134242/0/en/BioAge-Labs-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-BGE-102-a-Novel-Brain-Penetrant-NLRP3-Inhibitor.html
Aug 15, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next